← Back to Search

Monoclonal Antibodies

Epratuzumab for Non-Hodgkin's Lymphoma

Phase 2
Waitlist Available
Led By Christos E. Emmanouilides, MD
Research Sponsored by Jonsson Comprehensive Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Histologically confirmed diffuse large B-cell non-Hodgkin's lymphoma (NHL)
Relapsed or refractory after at least 1 regimen of standard therapy
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights

Study Summary

This trial will compare epratuzumab to rituximab to see which is more effective in treating non-Hodgkin's lymphoma.

Who is the study for?
This trial is for adults over 18 with diffuse large B-cell non-Hodgkin's lymphoma that has returned or resisted treatment. They should have measurable disease, a life expectancy of at least 4 months, and adequate organ function. Excluded are those with HIV-related lymphoma, certain other cancers within the last 3 years, serious infections or conditions, known allergies to murine proteins, pregnant or nursing women, and those not using effective contraception.Check my eligibility
What is being tested?
The trial is testing epratuzumab's effectiveness in patients with non-Hodgkin's lymphoma. Epratuzumab is a monoclonal antibody designed to target and kill tumor cells while sparing normal ones. This phase II study randomly assigns participants to receive epratuzumab to evaluate its impact on their cancer.See study design
What are the potential side effects?
Epratuzumab may cause side effects such as infusion reactions (symptoms related to the administration of the drug), potential harm to normal cells leading to low blood counts or immune system issues, allergic reactions due to its mouse protein origin, and fatigue.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with a type of lymphoma called diffuse large B-cell.
Select...
My condition did not improve after at least one standard treatment.
Select...
I am able to get out of my bed or chair and move around.
Select...
My kidney function, measured by creatinine, is within normal limits.
Select...
I am 18 years old or older.
Select...
My liver functions are within acceptable limits and I don't have hepatitis B or C.
Select...
I have a tumor that is larger than 1.5 cm, confirmed by a CT scan.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Find a Location

Who is running the clinical trial?

Jonsson Comprehensive Cancer CenterLead Sponsor
358 Previous Clinical Trials
26,076 Total Patients Enrolled
27 Trials studying Lymphoma
400 Patients Enrolled for Lymphoma
National Cancer Institute (NCI)NIH
13,609 Previous Clinical Trials
40,915,646 Total Patients Enrolled
1,376 Trials studying Lymphoma
381,584 Patients Enrolled for Lymphoma
Christos E. Emmanouilides, MDPrincipal InvestigatorJonsson Comprehensive Cancer Center
11 Previous Clinical Trials
50 Total Patients Enrolled
9 Trials studying Lymphoma
50 Patients Enrolled for Lymphoma

Media Library

Epratuzumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT00042913 — Phase 2
Lymphoma Research Study Groups:
Lymphoma Clinical Trial 2023: Epratuzumab Highlights & Side Effects. Trial Name: NCT00042913 — Phase 2
Epratuzumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT00042913 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are more participants welcome to join this trial?

"Per the information found on clinicaltrials.gov, this particular trial is no longer actively recruiting candidates; however it was initially posted in May of 2002 and last updated in December of 2013. While recruitment has ended for this study, there are 1,749 other medical studies currently accepting patients at present."

Answered by AI

Has this treatment been given the green light by federal regulators?

"Due to the Phase 2 status of this trial, there is only limited proof that suggests its safety - resulting in a score of two."

Answered by AI
~15 spots leftby Mar 2025